Travere Therapeutics Inc (TVTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Travere Therapeutics Inc (TVTX) has a cash flow conversion efficiency ratio of -0.409x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-40.37 Million) by net assets ($98.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Travere Therapeutics Inc to measure how many days the company can operate on defensive assets alone.
Travere Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2010–2025)
This chart illustrates how Travere Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Travere Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Travere Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bohai Leasing Co Ltd
SHE:000415
|
0.138x |
|
Minera Frisco S.A.B. de C.V
MX:MFRISCOA-1
|
0.291x |
|
Glarun Technology Co Ltd
SHG:600562
|
-0.001x |
|
Delek Group
TA:DLEKG
|
0.004x |
|
Shandong Intco Medical Products Co Ltd
SHE:300677
|
0.024x |
|
L&T Technology Services Limited
NSE:LTTS
|
0.076x |
|
Southwest Securities Co Ltd
SHG:600369
|
-0.255x |
|
Cosan SA ADR
NYSE:CSAN
|
0.029x |
Annual Cash Flow Conversion Efficiency for Travere Therapeutics Inc (2010–2025)
The table below shows the annual cash flow conversion efficiency of Travere Therapeutics Inc from 2010 to 2025. For the full company profile with market capitalisation and key ratios, see TVTX stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $114.83 Million | $37.78 Million | 0.329x | +108.19% |
| 2024-12-31 | $59.08 Million | $-237.47 Million | -4.020x | -188.27% |
| 2023-12-31 | $200.81 Million | $-280.02 Million | -1.394x | +67.92% |
| 2022-12-31 | $42.85 Million | $-186.29 Million | -4.347x | -8779.16% |
| 2021-12-31 | $302.11 Million | $-14.79 Million | -0.049x | +75.81% |
| 2020-12-31 | $211.21 Million | $-42.74 Million | -0.202x | +23.11% |
| 2019-12-31 | $221.20 Million | $-58.21 Million | -0.263x | -235.59% |
| 2018-12-31 | $318.25 Million | $-24.96 Million | -0.078x | -410.52% |
| 2017-12-31 | $293.13 Million | $7.40 Million | 0.025x | +587.00% |
| 2016-12-31 | $307.77 Million | $-1.60 Million | -0.005x | -180.79% |
| 2015-12-31 | $299.97 Million | $-554.00K | -0.002x | -100.15% |
| 2014-12-31 | $-37.25 Million | $-45.85 Million | 1.231x | +28.14% |
| 2013-12-31 | $-18.31 Million | $-17.59 Million | 0.961x | +19.61% |
| 2012-12-31 | $-3.41 Million | $-2.74 Million | 0.803x | +103283.92% |
| 2011-12-31 | $-63.08K | $-49.00 | 0.001x | -93.21% |
| 2010-12-31 | $-60.26K | $-689.00 | 0.011x | -- |
About Travere Therapeutics Inc
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola a… Read more